CNBC February 20, 2025
Key Points
– Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound are transforming the company.
– Lilly now has an obligation to take on other challenging diseases like Alzheimer’s, ALS and chronic pain, said the the company’s Chief Scientific Officer Dan Skovronsky.
– Lilly is already testing its drug Kisunla for Alzheimer’s prevention.
Heart disease. Hearing loss. Addiction. Chronic pain. Alzheimer’s. ALS. These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big bets.
These are the ideas that are “hiding in plain sight,” said Lilly Chief Scientific Officer Dan Skovronsky. They’re places where other pharmaceutical companies might not want to go because they’re hard problems to solve.
“As right...
Today's Sponsors
Today's Sponsor